Workflow
icon
Search documents
年底电力现货市场全覆盖,重视灵活调节电源价值
GOLDEN SUN SECURITIES· 2025-05-05 11:17
电力 年底电力现货市场全覆盖,重视灵活调节电源价值 本周行情回顾:本周(4.28-4.30)上证指数报收 3,279.03 点,下跌 0.49%, 沪深 300 指数报收 3770.57 点,下跌 0.43%。中信电力及公用事业指数 报收 2846.13 点,下跌 1.68%,跑输沪深 300 指数 1.24pct,位列 30 个 中信一级板块涨跌幅榜第 23 位。 本周行业观点: 今年年底电力现货市场基本全面覆盖,电力市场化不断加深,辅助服 务需求有望进一步提升,建议重视灵活调节电源配置价值。 ➢ 国常会新核准核电 10 台机组,成长确定性再加码。4 月 27 日,经 国务院常务会议审议,决定核准 5 个核电项目,合计 10 台机组。具 体为中核三门核电 5/6 号机组、中广核广西防城港核电 5/6 号机组、 广东台山核电 3/4 号机组,国家电投海阳核电 5/6 号,以及华能霞浦 核电 1/2 号机组。其中,华龙一号机组 8 台,CAP1000 机组 2 台。 2019 年-2025 年,我国核准核电机组数量分别为 6/4/5/10/10/11/10 台,已经连续 4 年核准 10 台及以上,7 年累计核 ...
纺织服饰周专题:adidas公司2025Q1营收增长13%,表现优异
GOLDEN SUN SECURITIES· 2025-05-05 11:17
证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 纺织服饰 周专题:adidas 公司 2025Q1 营收增长 13%,表现优异 【本周专题】 adidas 公司 2025Q1 营收增长 13%,表现超预期。adidas 披露 2025Q1 季 报,货币中性基础上营收同比增长 13%至 61.53 亿欧元,毛利率同比提升 0.9pcts 至 52.1%,经营利润同比大幅增长 82%至 6.1 亿欧元。截至 3 月末公司 库存同比增长 15%至 50.72 亿欧元,库存增加主要为了支持业务发展,库存处于 健康状态。 展望 2025 年:公司维持此前对于 2025 年的指引,预计 2025 年公司营收同比 增长高单位数,其中 adidas 品牌营收同比增长双位数。2025Q1 整体表现超公司 预期,然而当前美国关税问题或对公司业绩造成负面影响,综合考虑 Q1 表现以 及关税事件的不确定性因素后,公司维持此前指引。 分地区看:2025Q1 欧洲/大中华区业务增长亮眼,拉丁美洲业务持续快速增长。 1)欧洲&北美:货币中性基础上 2025Q1 北美业务营收同比增长 2.8%至 11 ...
继续关注二手房成交对建材需求的影响
GOLDEN SUN SECURITIES· 2025-05-05 11:17
Investment Rating - The report maintains a "Buy" rating for several companies in the construction materials sector, including Puhua Co., China Jushi, Beixin Building Materials, and Yixing New Materials, while recommending "Hold" for Weixing New Materials [9]. Core Insights - The construction materials sector is experiencing a weak recovery, with cement prices fluctuating around the industry average without profitability [3][17]. - The demand for glass is showing seasonal improvement, but there are still supply-demand contradictions, with expectations of price fluctuations [4][34]. - The report emphasizes the positive impact of second-hand housing transactions and consumption stimulus policies on the demand for consumer building materials, recommending companies like Beixin Building Materials and Weixing New Materials [2][4]. Summary by Sections Cement Industry Tracking - As of April 30, 2025, the national cement price index is 379.72 yuan/ton, down 1.62% week-on-week, with a cement output of 3.545 million tons, up 0.7% [3][17]. - The cement industry is in a weak recovery phase, with construction demand being the main driver, but regional performance varies significantly [17]. Glass Industry Tracking - The average price of float glass is 1331.98 yuan/ton, with a slight increase of 0.02% week-on-week, and inventory levels are up year-on-year [4][34]. - Market demand remains moderate, and there is a lack of pre-holiday replenishment from downstream sectors [34]. Fiberglass Industry Tracking - The fiberglass market is experiencing weak demand, with prices under pressure due to increased supply and low operating rates in downstream processing plants [7]. - The report highlights the potential for price increases in high-end products due to strong demand [7]. Carbon Fiber Market Tracking - The carbon fiber market shows stable production levels, with a weekly output of 1679 tons and an operating rate of 60.62% [8]. - The report notes a gradual recovery in downstream demand, particularly in wind energy and hydrogen storage sectors [8]. Key Stocks - Recommended stocks include Puhua Co. (Buy), China Jushi (Buy), Beixin Building Materials (Buy), and Weixing New Materials (Hold) [9].
华大智造:25Q1业绩短期承压,国产替代加速2025业绩可期-20250505
GOLDEN SUN SECURITIES· 2025-05-05 10:23
Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's gene sequencing instrument business is experiencing steady growth, with significant progress in instrument installations. Despite short-term revenue pressure in Q1 2025 due to seasonal fluctuations, profit performance is driven by cost reduction and efficiency improvements. The acceleration of domestic substitution in 2025 is expected to lead to rapid growth in performance [2][4] Summary by Sections Financial Performance - In 2024, the company achieved revenue of 3.013 billion yuan, a year-on-year increase of 3.48%. The net profit attributable to the parent company was -601 million yuan, a year-on-year increase of 1.10%. The adjusted net profit was -653 million yuan, a year-on-year increase of 4.41%. In Q4 2024, revenue reached 1.143 billion yuan, a year-on-year increase of 61.64% [1] - For Q1 2025, the company reported revenue of 455 million yuan, a year-on-year decline of 14.26%. The net profit attributable to the parent company was -133 million yuan, a year-on-year increase of 33.67% [1][2] Business Segments - The gene sequencing instrument business generated revenue of 2.348 billion yuan in 2024, a year-on-year increase of 2.47%. Instrument revenue was 960 million yuan (up 6.92%), and reagent revenue was 1.373 billion yuan (up 1.43%). The laboratory automation business generated 209 million yuan (down 4.09%) [2] - In Q1 2025, the company launched several new products, including the DNBSEQ-AIO library preparation sequencer and the DNBSEQ-E25 Flash sequencer, which are expected to strengthen future growth [4] International Expansion - The company has established a global presence across over 110 countries, with nine R&D centers, seven production bases, and nine international spare parts warehouses. In 2024, overseas revenue from the gene sequencing instrument business was 741 million yuan, a year-on-year decrease of 12.66% [3] - The company has made significant strides in localizing its operations, with the U.S. factory now operational and producing the DNBSEQ-G99 sequencer [3] Future Projections - Revenue projections for 2025-2027 are 3.736 billion yuan, 4.306 billion yuan, and 4.959 billion yuan, representing year-on-year growth rates of 24.0%, 15.3%, and 15.2%, respectively. The net profit attributable to the parent company is expected to improve significantly, reaching -57 million yuan in 2025 and 144 million yuan in 2026 [4][5]
迈瑞医疗:政策扰动下25Q1短期承压,招标恢复趋势下看好业绩逐季改善-20250505
GOLDEN SUN SECURITIES· 2025-05-05 10:23
证券研究报告 | 年报点评报告 gszqdatemark 2025 05 05 年 月 日 迈瑞医疗(300760.SZ) 政策扰动下 25Q1 短期承压,招标恢复趋势下看好业绩逐季改善 迈瑞医疗发布 2024 年度报告。2024 年公司实现营业收入 367.26 亿元,同比增长 5.14%;归母净利润 116.68 亿元,同比增长 0.74%;扣非后归母净利润 114.42 亿元, 同比增长 0.07%。分季度看,2024Q4 实现营业收入 72.41 亿元,同比下滑 5.08%;归 母净利润 10.31 亿元,同比下滑 40.99%;扣非后归母净利润 10.05 亿元,同比下滑 42.49%。 迈瑞医疗发布 2025 年度一季报。2025Q1 公司实现营业收入 82.37 亿元,同比下滑 12.12%;归母净利润 26.29 亿元,同比下滑 16.81%;扣非后归母净利润 25.31 亿元, 同比下滑 16.68%。 观点:2024 年体外诊断业务稳健增长,高端超声 A20 放量驱动医学影像板块增长, 种子业务蓄势待发,多产品线各放异彩。2025Q1 业绩阶段性承压,主要系国内政策 扰动及海外同期高基数影 ...
电力设备行业周报:海上风电迎来密集开工,英联股份持续拓宽复合集流体合作版图
GOLDEN SUN SECURITIES· 2025-05-05 10:23
海上风电迎来密集开工,英联股份持续拓宽复合集流体合作版图 光伏:硅料价格继续下跌,成交价环比下降 2.6~2.7%。根据硅料分会报道, 随着 5、6 月下游排产开始下调,本周硅料价格继续下跌。n 型复投料成交价 格区间为 3.70-4.50 万元/吨,成交均价为 3.92 万元/吨,环比下降 2.73%;n 型颗粒硅成交价格区间为 3.60-3.80 万元/吨,成交均价为 3.70 万元/吨,环比 下降 2.63%;p 型多晶硅成交价格区间为 3.10-3.50 万元/吨,成交均价为 3.23 万元/吨,环比下降 2.12%。目前预计 5 月硅料排产在 10 万吨左右,关注后 续降排产情况。核心关注两大方向:1)供给侧偏刚性、后续需求复苏后价格 弹性更大的硅料和玻璃,核心关注协鑫科技、通威股份、福莱特等。2)新技 术背景下带来的中长期成长性机会,核心关注爱旭股份、聚和材料等。 风电&电网:海上风电迎来密集开工。包括华能山东半岛北 L 场址海上风电项 目、浙江舟山普陀 2#海上风电场项目开工、瑞安 2 号 600MW。风电板块, 关注海缆:东方电缆、中天科技、亨通光电、起帆电缆,桩基:天顺风能、海 力风电、大金 ...
钢铁行业周报:约束供给扩大消费
GOLDEN SUN SECURITIES· 2025-05-05 10:23
增持(维持) 证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 钢铁 约束供给扩大消费 行情回顾(4.28-4.30): 中信钢铁指数报收 1,528.72 点,下跌 0.52%,跑输沪深 300 指数 0.09pct,位列 30 个中信 一级板块涨跌幅榜第 16 位。 重点领域分析: 投资策略:受假期影响本周交易日有限,海外交易市场贵金属价格出现一定的调整,黑色商 品则依然震荡。根据财联社,宝钢回应近期钢铁市场传闻行业将限产 5000 万吨以应对近年 来市场供需结构的变化是大概率事件,但随后黑色商品价格表现平淡,行业内对今年限产落 实疑虑较大。由于过去在执行中存在一定的落实障碍,加之今年的监督和奖惩还缺少更多的 细节,市场抱有一定的疑虑是正常的。中国"内卷"很大原因是由于地方政府尤其青睐重资 产的制造业,一是因为投资规模大,对 GDP 拉动作用明显;二是因为增值税在生产环节征 收,跟生产规模直接挂钩;三是因为制造业不仅可以吸纳从农业部门转移出的低技能劳动力, 也可以带动第三产业发展,增加相关税收。因为绝大多数税收征收自企业,且多在生产环节 征收,所以过去地方政府重视企业 ...
联影医疗:Q1业绩迎来复苏,海外高端与新兴市场取得双重突破-20250505
GOLDEN SUN SECURITIES· 2025-05-05 10:23
Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's performance in 2024 faced temporary pressure due to domestic industry restructuring and equipment update cycles, while overseas markets experienced rapid growth. The first quarter of 2025 showed positive year-on-year growth in both revenue and profit, indicating a gradual release of equipment update demand. The company achieved breakthroughs in high-end markets and penetration in emerging regions, enhancing its global presence as a leading domestic medical imaging company [2][3] Financial Performance Summary - In 2024, the company reported revenue of 10.3 billion yuan, a year-on-year decline of 9.73%, and a net profit attributable to shareholders of 1.262 billion yuan, down 36.09%. The first quarter of 2025 saw revenue of 2.478 billion yuan, an increase of 5.42%, and a net profit of 370 million yuan, up 1.87% [1][5] - The service business showed strong performance in 2024, with revenue of 1.356 billion yuan, a year-on-year increase of 26.80%, and a gross margin of 63.43%. In contrast, the equipment business faced challenges, with revenue of 8.445 billion yuan, a decline of 14.93% [2][3] - The company's overseas revenue reached 2.22 billion yuan in 2024, a year-on-year increase of 33.81%, while domestic revenue was 7.664 billion yuan, down 19.43% [3] Product and Market Development - The company has launched over 140 innovative products by the end of 2024, with significant certifications including 46 CE MDR and 49 FDA approvals. Notable products include advanced MRI and CT systems, enhancing the company's product portfolio [4] - The company has expanded its overseas business to over 85 countries and regions, achieving significant market penetration in North America and Europe, and making strides in emerging markets such as India, Turkey, Mexico, and Brazil [3][4] Future Projections - Revenue projections for 2025 to 2027 are estimated at 12.354 billion yuan, 15.130 billion yuan, and 18.326 billion yuan, respectively, with year-on-year growth rates of 19.9%, 22.5%, and 21.1%. Net profit projections for the same period are 1.803 billion yuan, 2.245 billion yuan, and 2.746 billion yuan, with growth rates of 42.8%, 24.6%, and 22.3% [4][5]
新产业:Q1海外市场延续高增,高端机型持续突破-20250505
GOLDEN SUN SECURITIES· 2025-05-05 10:23
证券研究报告 | 年报点评报告 gszqdatemark 2025 05 05 年 月 日 新产业(300832.SZ) Q1 海外市场延续高增,高端机型持续突破 新产业发布 2024 年度报告。2024 年公司实现营业收入 45.35 亿元,同比增长 15.41%;归母净利润 18.28 亿元,同比增长 10.57%;扣非后归母净利润 17.20 亿元,同比增长 11.19%。分季度看,2024Q4 实现营业收入 11.21 亿元,同比增 长 9.75%;归母净利润 4.45 亿元,同比下滑 4.73%;扣非后归母净利润 3.90 亿 元,同比下滑 12.58%。 新产业发布 2025 年度一季报。2025Q1 公司实现营业收入 11.25 亿元,同比增长 10.12%;归母净利润 4.38 亿元,同比增长 2.65%;扣非后归母净利润 4.17 亿元, 同比增长 4.39%。 观点:2024 年海外市场表现靓丽,国内市场在集采压力下依旧实现稳健增长。 2025Q1 海外市场延续高增态势,利润端增速不及收入端,主要系集采压力下毛 利率波动影响。海内外高端机型装机进展顺利,三级医院覆盖率持续提升,海外 本土化 ...
海上风电迎来密集开工,英联股份持续拓宽复合集流体合作版图
GOLDEN SUN SECURITIES· 2025-05-05 09:20
电力设备 海上风电迎来密集开工,英联股份持续拓宽复合集流体合作版图 光伏:硅料价格继续下跌,成交价环比下降 2.6~2.7%。根据硅料分会报道, 随着 5、6 月下游排产开始下调,本周硅料价格继续下跌。n 型复投料成交价 格区间为 3.70-4.50 万元/吨,成交均价为 3.92 万元/吨,环比下降 2.73%;n 型颗粒硅成交价格区间为 3.60-3.80 万元/吨,成交均价为 3.70 万元/吨,环比 下降 2.63%;p 型多晶硅成交价格区间为 3.10-3.50 万元/吨,成交均价为 3.23 万元/吨,环比下降 2.12%。目前预计 5 月硅料排产在 10 万吨左右,关注后 续降排产情况。核心关注两大方向:1)供给侧偏刚性、后续需求复苏后价格 弹性更大的硅料和玻璃,核心关注协鑫科技、通威股份、福莱特等。2)新技 术背景下带来的中长期成长性机会,核心关注爱旭股份、聚和材料等。 风电&电网:海上风电迎来密集开工。包括华能山东半岛北 L 场址海上风电项 目、浙江舟山普陀 2#海上风电场项目开工、瑞安 2 号 600MW。风电板块, 关注海缆:东方电缆、中天科技、亨通光电、起帆电缆,桩基:天顺风能、海 力 ...